

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT06063486

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Southern California
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Age ≥ 18
- Eastern Cooperative Oncology Group (ECOG) ≤ 2
- Ability to understand and willingness to sign a written informed consent
- Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria
- Presence of at least one symptom measurable using the MPN-/Symptom Assessment Form (SAF) with a severity greater than 3

Exclusion (10)

- A diagnosis of CCUS or LR-MDS
- CCUS defined as persistent cytopenia for > 6 months (hemoglobin $[Hgb] < 11.3$ g/dL $[7$ mmol/L] in women and Hgb < 12.9 g/dL $[8$ mmol/L] in men, platelet $< 150 \times 10^9/L$ or neutrophils $< 1.8 \times 10^9/L$), normal cytogenetics, presence of detectable MDS associated mutations and bone marrow morphology non-diagnostic of MDS or any other malignancies
- LR-MDS as defined by WHO 2016 diagnosis criteria
- Minimum baseline symptom score of 25 in the fatigue section of the symptom questionnaire
- Patients with intake of curcumin as a dietary supplement, including multivitamin and unwillingness to quit more than 24 hours before study start
- ... and 5 more (see full listing online)

Locations (2 total)

Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

<https://clinicaltrials.gov/study/NCT06063486>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.